– SEC Filing
ANI Pharma’s Posts Mixed Bag Q4 Earnings, FY22 Sales Outlook Trails Street Consensus
ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Q4 revenues were $60.9 million, +6.4% Y/Y, beating the consensus of $56.30 million. Net revenues for…
Related Posts
Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?
TransCode Therapeutics Inc (NASDAQ:RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. …
Barclays Maintains Overweight on Hess, Raises Price Target to $131
Barclays analyst Jeanine Wai maintains Hess (NYSE:HES) with a Overweight and raises the price target from $124 to $131.
Piper Sandler Downgrades Great Southern Bancorp to Neutral, Announces $63 Price Target
Piper Sandler analyst Andrew Liesch downgrades Great Southern Bancorp (NASDAQ:GSBC) from Overweight to Neutral and announces $63 price target.